Yeast systems for demonstrating the targets of anti-topoisomerase II agents.
Nitiss
J L
JL
Molecular Pharmacology Department, St. Jude Children's Research Hospital, Memphis, TN, USA.
Nitiss
K C
KC
D000970:Antineoplastic Agents / Q000494:pharmacology; D003470:Culture Media / Q000737:chemistry; D004264:DNA Topoisomerases, Type I / Q000235:genetics / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000378:metabolism; D004352:Drug Resistance, Microbial / Q000235:genetics*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D017353:Gene Deletion; D015966:Gene Expression Regulation, Fungal; D005800:Genes, Fungal / Q000235:genetics; D006801:Humans; D012441:Saccharomyces cerevisiae / Q000187:drug effects* / Q000201:enzymology* / Q000235:genetics / Q000254:growth & development; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014170:Transformation, Genetic
D000970:Antineoplastic Agents; D003470:Culture Media; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II